Strategic Wealth Partners Ltd. Invests $839,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

Strategic Wealth Partners Ltd. purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 54,204 shares of the company’s stock, valued at approximately $839,000.

Several other hedge funds have also made changes to their positions in the business. Certuity LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at approximately $109,000. Belpointe Asset Management LLC raised its holdings in Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after acquiring an additional 1,205 shares in the last quarter. Custom Index Systems LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at approximately $132,000. B. Riley Wealth Advisors Inc. acquired a new stake in Hims & Hers Health in the fourth quarter valued at approximately $155,000. Finally, Avantax Advisory Services Inc. acquired a new stake in Hims & Hers Health in the first quarter valued at approximately $156,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total transaction of $45,188.00. Following the completion of the transaction, the insider now owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Andrew Dudum sold 45,755 shares of Hims & Hers Health stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $22.97, for a total transaction of $1,050,992.35. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $769,540.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $22.00, for a total value of $45,188.00. Following the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. The disclosure for this sale can be found here. Over the last quarter, insiders sold 782,901 shares of company stock valued at $16,138,997. 17.71% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

HIMS has been the topic of several analyst reports. Jefferies Financial Group raised their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Citigroup lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and increased their price target for the company from $16.00 to $20.00 in a research note on Wednesday, May 22nd. Piper Sandler increased their price target on shares of Hims & Hers Health from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, July 11th. TD Cowen increased their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Finally, Seaport Res Ptn reiterated a “buy” rating on shares of Hims & Hers Health in a research note on Friday, April 26th. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.07.

Hims & Hers Health Stock Down 5.1 %

NYSE:HIMS traded down $0.95 during midday trading on Friday, reaching $17.56. The stock had a trading volume of 11,350,296 shares, compared to its average volume of 7,605,596. The firm has a fifty day simple moving average of $21.36 and a two-hundred day simple moving average of $15.57. Hims & Hers Health, Inc. has a 12-month low of $5.65 and a 12-month high of $25.74. The stock has a market cap of $3.77 billion, a P/E ratio of -1,756.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. During the same quarter last year, the company earned ($0.05) earnings per share. Hims & Hers Health’s quarterly revenue was up 45.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.2 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.